Fed. Cir.

Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 17-2636 (Fed. Cir. June 12, 2019)

Errata

Court: U.S. Court of Appeals for the Federal Circuit
Case No.: No. 17-2636
Also Docketed: No. 18-1320 (consolidated; same document)
Decided: June 12, 2019
Judge: —
Document: Errata
Length: 2 pages

Full Text Analysis Cite this Opinion

Download Opinion (PDF)

NOTE: This disposition is nonprecedential. United States Court of Appeals

for the Federal Circuit

July 11, 2019

ERRATUM

Appeal No. 2017-2312

DR. FALK PHARMA GMBH,

Appellant

GENERICO, LLC, FLAT LINE CAPITAL LLC,

MYLAN PHARMACEUTICALS INC.,

Appellees

Appeal Nos. 2017-2636, 2018-1320

SALIX PHARMACEUTICALS, INC., DR. FALK

PHARMA GMBH,

Plaintiffs-Appellants

MYLAN PHARMACEUTICALS INC., MYLAN INC.,

Defendants-Appellees

Decided June 12, 2019

Nonprecedential Opinion

22 DR. FALK PHARMA GMBH v. GENERICO, LLC

The following change has been made: Page 16, line 16, “district court” has been changed to “Board.”

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 17-2636 (Fed. Cir. June 12, 2019).

govinfo ID: USCOURTS-ca13-17-02636-1
Permalink: https://patentcasewatch.com/opinions/USCOURTS-ca13-17-02636-1

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.

Source: govinfo.gov USCOURTS collection · retrieved July 25, 2026 · Report an error